Multimodal imaging in the characterization of tumors to assess tumor aggressiveness, diagnostic work-up and treatment response evaluation in prostate cancer, cervical cancer, breast cancer, sarcomas, spinal metastases, neuroendocrine tumors, GISTs, colorectal cancers, liver malignancies, multiple myeloma and lymphoma
Characterization of vascular inflammation inclusive vulnerability in atherosclerosis, treatment selection and treatment response evaluation using PET, MRI and US
Detection and treatment response evaluation in inflammatory and fibrosing diseases using different imaging modalities and PET tracers
Characterize pituritary microadenomas, remnant adenomas following surgery and hypophysitis by the use of different MRI and PET techniques
Radionuclide therapies for treatment of non-Hodgkin lymphoma, neuroendocrine tumors (NET) and Selective Internal Radiation Therapy (SIRT)
Development and testing of novel radionuclide therapies with emphasis on alpha-emitters
Molecular imaging and quantification of neurological diseases
Ultrasound-guided percutaneous ethanol injection treatment in patients with metastatic lymph nodes from thyroid carcinoma
Development of new biomarkers using radiomics and artificial intelligence (AI) for the characterization of diseases
Müller EG, Dahlberg D, Hassel B, Revheim ME, Connelly JP(2024) Brain Abscess Causes Brain Damage With Long-Lasting Focal Cerebral Hypoactivity that Correlates With Abscess Size: A Cross-Sectional 18F-Fluoro-Deoxyglucose Positron Emission Tomography Study Neurosurgery(in press) DOI 10.1227/neu.0000000000003268, PubMed 39526777
Stern NM, Mikalsen LTG, Dueland S, Schulz A, Line PD, Stokke C, Grut H(2024) The prognostic value of [18F]FDG PET/CT texture analysis prior to transplantation for unresectable colorectal liver metastases Clin Physiol Funct Imaging, 45(1), e12908 DOI 10.1111/cpf.12908, PubMed 39358976
Skingen VE, Salberg UB, Hompland T, Fjeldbo CS, Helgeland H, Frikstad KM, Ragnum HB, Vlatkovic L, Hole KH, Seierstad T, Lyng H(2024) Spatial analysis of microRNA regulation at defined tumor hypoxia levels reveals biological traits of aggressive prostate cancer J Pathol, 264(3), 270-283 DOI 10.1002/path.6344, PubMed 39329425